STATINS & NEWER HOPE FOR ATHEROSCLEROSIS ASSOCIATED DISEASES.
作者信息
Sharma S K
机构信息
Classified Specialist (Medicine), Military Hospital, Jodhpur.
出版信息
Med J Armed Forces India. 2001 Apr;57(2):129-30. doi: 10.1016/S0377-1237(01)80131-3. Epub 2011 Jul 21.
Abstract
摘要
相似文献
1
STATINS & NEWER HOPE FOR ATHEROSCLEROSIS ASSOCIATED DISEASES.他汀类药物与动脉粥样硬化相关疾病的新希望。
Med J Armed Forces India. 2001 Apr;57(2):129-30. doi: 10.1016/S0377-1237(01)80131-3. Epub 2011 Jul 21.
2
Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease.他汀类药物治疗强度与动脉粥样硬化性心血管疾病患者死亡率的关系。
JAMA Cardiol. 2017 Jan 1;2(1):47-54. doi: 10.1001/jamacardio.2016.4052.
3
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.依泽替米贝和辛伐他汀治疗高胆固醇血症减少动脉粥样硬化进展试验（ENHANCE）结果报告前后处方模式的变化，以及对降低低密度脂蛋白胆固醇的预期影响。
J Clin Lipidol. 2012 Mar-Apr;6(2):180-91. doi: 10.1016/j.jacl.2011.11.007. Epub 2011 Dec 7.
4
Exploring new indications for statins beyond atherosclerosis: Successes and setbacks.探讨他汀类药物除动脉粥样硬化以外的新适应证：成败得失。
J Cardiol. 2010 Mar;55(2):155-62. doi: 10.1016/j.jjcc.2009.12.003. Epub 2010 Jan 7.
6
Understanding the Effect of Statins and Patient Adherence in Atherosclerosis via a Quantitative Systems Pharmacology Model Using a Novel, Hybrid, and Multi-Scale Approach.通过一种新颖、混合且多尺度的方法，利用定量系统药理学模型理解他汀类药物和患者依从性在动脉粥样硬化中的作用。
Front Pharmacol. 2017 Sep 13;8:635. doi: 10.3389/fphar.2017.00635. eCollection 2017.
7
Nonutilization of Statins in a Community-based Population with a History of Coronary Revascularization.在有冠状动脉血运重建史的社区人群中他汀类药物的未使用情况。
Clin Ther. 2016 Feb;38(2):288-296.e2. doi: 10.1016/j.clinthera.2015.11.020. Epub 2015 Dec 22.
8
Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms.他汀类药物会引发动脉粥样硬化和心力衰竭：药理机制。
Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99. doi: 10.1586/17512433.2015.1011125. Epub 2015 Feb 6.
9
National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.2002 年至 2013 年美国成年人群体中他汀类药物的使用和支出的国家趋势：来自医疗支出调查的见解。
JAMA Cardiol. 2017 Jan 1;2(1):56-65. doi: 10.1001/jamacardio.2016.4700.
10
A New HOPE? Lessons from Heart Outcomes Prevention Evaluation-3.新的希望？心脏结局预防评估 3 期的经验教训。
Am J Med. 2018 Feb;131(2):134-140. doi: 10.1016/j.amjmed.2017.10.012. Epub 2017 Oct 23.
本文引用的文献
1
Implications of lipoprotein abnormalities in Indian patients.印度患者脂蛋白异常的影响。
J Assoc Physicians India. 1998 Sep;46(9):814-8.
2
3
The 4S study. Implications for prescribing.4S研究。对处方开具的启示。
Drugs. 1996 Apr;51(4):507-14. doi: 10.2165/00003495-199651040-00001.
4
Scandinavian simvastatin study (4S).斯堪的纳维亚辛伐他汀研究（4S）
Lancet. 1994;344(8939-8940):1765-6; author reply 1767-8.
5
6
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS).辛伐他汀对冠状动脉粥样硬化的影响：多中心抗动脉粥样硬化研究（MAAS）。
Lancet. 1994 Sep 3;344(8923):633-8.
7
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).降低冠状动脉事件风险：来自斯堪的纳维亚辛伐他汀生存研究（4S）的证据。
Am J Cardiol. 1995 Sep 28;76(9):64C-68C. doi: 10.1016/s0002-9149(99)80473-1.
8
Pattern of ischaemic heart disease: a clinical study.缺血性心脏病模式：一项临床研究。
J Indian Med Assoc. 1970 Sep 1;55(5):153-7.
9
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.载脂蛋白B水平高的男性强化降脂治疗后冠状动脉疾病的消退
N Engl J Med. 1990 Nov 8;323(19):1289-98. doi: 10.1056/NEJM199011083231901.
Zotero 插件